Oncomatryx, a Zamudio, Spain-based biopharmaceutical company developing novel ADCs against the tumor microenvironment, raised €25M in funding.
The round was led by existing investors and included a €10M strategic investment from Centro para el Desarrollo Tecnológico y la Innovación.
The company intends to use the funds to expand operations and its R&D sector.
Led by CEO Dr. Laureano Simon, Oncomatryx has developed a proprietary antibody-drug conjugates platform that targets cancer-associated fibroblasts in the microenvironment of metastatic solid tumors. Its ADCs against immunosuppressive CAFs are developed in collaboration with universities, hospitals and research centers in USA and Europe.
FinSMEs
27/01/2025